The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim

Abstract

Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients.Commentary on: Moulis et al. Difficult‐to‐treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN‐France Registry. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19288.